Related Experiment Video
Updated: Sep 14, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Novel way to increase targeting specificity to a human glioblastoma-associated receptor for interleukin 13
W Debinski1, D M Gibo, R K Puri
1Section of Neurosurgery, Pennsylvania State University College of Medicine, Hershey 17033-0850, USA. wdebinski@PSGHS.EDU
Abstract:
Human brain cancers (gliomas) overexpress large numbers of a receptor for interleukin 13 (IL13), making this receptor an attractive target for anti-glioma therapies. We have recently proposed that the glioma-associated IL13 receptor is different from the one expressed on some hemopoietic and somatic cells. In an attempt to identify an even more glioma-specific target, we have used an antagonist of a related cytokine, IL4, which neutralizes the physiological effects of both IL13 and IL4 on normal cells. Here we demonstrate that the IL4 antagonist also counteracts the action of cytotoxins targeted to the IL13 receptor on normal human cells. Importantly, the IL4 antagonist does not inhibit IL13-based cytotoxins on glioma cells at all. Thus, the IL13 receptor on glioma cells can be categorized as tumor-specific in the presence of an IL4 antagonist. We conclude that IL13 receptor-directed cytotoxins can be delivered to glioma cells without being cytotoxic to normal cells.
Insights
Interleukin 13 (IL13) receptor antagonists show promise for glioma treatment. An IL4 antagonist enhances IL13-based cytotoxin specificity, targeting brain tumors while sparing normal cells.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Human brain cancers, gliomas, frequently overexpress the interleukin 13 (IL13) receptor.
- This IL13 receptor presents a potential therapeutic target for novel anti-glioma strategies.
- A distinct IL13 receptor subtype on glioma cells, differing from hemopoietic and somatic cells, is hypothesized.
Purpose of the Study:
- To identify a more glioma-specific therapeutic target by utilizing an interleukin 4 (IL4) antagonist.
- To evaluate the efficacy of an IL4 antagonist in conjunction with IL13 receptor-targeted cytotoxins.
- To determine if IL13 receptor-directed cytotoxins can be made tumor-specific for gliomas.
Main Methods:
- Administration of an IL4 antagonist, which neutralizes both IL13 and IL4 effects on normal cells.
- Testing the effect of the IL4 antagonist on IL13 receptor-targeted cytotoxins in normal human cells.
- Assessing the impact of the IL4 antagonist on the efficacy of IL13-based cytotoxins specifically on glioma cells.
Main Results:
- The IL4 antagonist counteracted the action of IL13 receptor-targeted cytotoxins on normal human cells.
- Crucially, the IL4 antagonist did not inhibit the activity of IL13-based cytotoxins on glioma cells.
- These findings indicate that the IL13 receptor on glioma cells exhibits tumor-specific characteristics in the presence of an IL4 antagonist.
Conclusions:
- The IL13 receptor on glioma cells can be considered tumor-specific when an IL4 antagonist is present.
- IL13 receptor-directed cytotoxins can be effectively delivered to glioma cells.
- This approach offers a strategy to target brain tumors without causing cytotoxicity to normal cells, enhancing therapeutic safety.
